503A Compounded Peptides
PCAC-track directory — pending the July 23-24, 2026 vote.
On April 15, 2026, the FDA removed seven peptides from the Category 2 bulk-substances list. Under section 503A, that removal means these peptides cannot lawfully be compounded from bulk substances by 503A pharmacies until the Pharmacy Compounding Advisory Committee (PCAC) issues a ruling. PCAC reviewed all seven on July 23-24, 2026.
This directory pre-builds the post-vote landing infrastructure. Until PCAC renders a favorable ruling for a given peptide, the corresponding pharmacy listing remains intentionally empty. We do not publish speculative pharmacy directories.
The seven peptides under review
- Pending PCACCompounded BPC-157
PCAC review: 2026-07-23
Research-use vendor pricing remains live at /peptides/bpc-157.
- Pending PCACCompounded TB-500
PCAC review: 2026-07-23
Research-use vendor pricing remains live at /peptides/tb-500.
- Pending PCACCompounded MOTS-c
PCAC review: 2026-07-23
Research-use vendor pricing remains live at /peptides/mots-c.
- Pending PCACCompounded DSIP
PCAC review: 2026-07-23
Research-use vendor pricing remains live at /peptides/dsip.
- Pending PCACCompounded Epitalon
PCAC review: 2026-07-23
Research-use vendor pricing remains live at /peptides/epithalon.
- Pending PCACCompounded Semax
PCAC review: 2026-07-23
Research-use vendor pricing remains live at /peptides/semax.
- Pending PCACCompounded KPV
PCAC review: 2026-07-23
Research-use vendor pricing remains live at /peptides/kpv.
Methodology
Each entry above carries a per-peptide regulatory page that explains the current 503A status, links back to the research-use price comparison, and describes what changes if PCAC votes favorable or unfavorable. For broader sourcing and vendor-rating methodology, see Pepticker methodology and the educational hub at /learn.
Editorial overview of the regulatory landscape. Not legal or medical advice. See /methodology for sourcing.